Rosanne Sprute

Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer - PubMed Comprehensive literature search and expert panel consensus confirm most of the key recommendations of 2014. New recommendations on the use of G-CSF in immunotherapy settings provide insight and support for day-by-day clinical decision making in the care of patients with cancer.

New AGIHO guideline update on G-CSF prophylaxis in adult cancer patients! Evidence-based recommendations incl. immunotherapy settings, biosimilars & risk stratification to support clinical decision-making.
🔗 pubmed.ncbi.nlm.nih.gov/41570611/
@rosannesprute.bsky.social
#Oncology #Guidelines

Optimising the management of invasive candidiasis

Proud to share our new CMI editorial with @rosannesprute.bsky.social: we highlight the rising challenges in invasive candidiasis-shifting epidemiology, antifungal resistance, precision therapy, and the global threat of C. auris. www.sciencedirect.com/science/arti...
#MedicalMycology #Candida

Get ready for a feast of fungal biology at the GRC CMFB conference in Holderness, NH next year. @mrccmm.bsky.social @youngecmm.bsky.social @ishamycology.bsky.social @youngisham.bsky.social @britmycolsoc.org.uk @elainebignell.bsky.social

Gender differences in audience participation at infectious disease and microbiology conferences: a prospective observational study In medicine, women constitute a large proportion of the workforce but remain underrepresented in senior positions. Scientific conferences, critical for career advancement, reflect these inequities, wi...

www.clinicalmicrobiologyandinfection.org/article/S119...

🎧 Infektiopod #99: Candidiasis
Gemeinsam mit @rosannesprute.bsky.social spreche ich über die neue globale Leitlinie zur Diagnose und zum Management von Candidiasis – von der Entstehung der Guideline bis zu Diagnostik und Therapie.
Jetzt reinhören: infektiopod.de/infektiopod-99-candidiasis/

It was a privilege to give a talk yesterday in the polymicrobial interactions & pathogenesis session about my work on the role of copper in Candida - bacterial interactions #Candida2025 @mrccmm.bsky.social @microbiologysociety.org thanks to the wonderful @rosannesprute.bsky.social for the picture

Highlights of ESCMID Global 2025 The 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases was held in Vienna, Austria, from April 11 to 15, 2025. Syeda Saleha Hassan reports.

Proud to see key antifungal advances featured in The Lancet Infectious Diseases highlights of #ESCMIDGlobal2025.
@rosannesprute.bsky.social presented global candidiasis guidelines; I shared FURI study results on ibrexafungerp efficacy.
👉 The Lancet article: www.thelancet.com/journals/lan...

✨📄 What about the untapped therapeutic potential of the immune response in invasive aspergillosis ? Here’s some rational, pre-clinical and clinical evidence. Huge thanks to our amazing 🌍 team!
🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social

Sugar Fingerprints to Fight Fungal Infections

Replicas of fungal #sugars decode the immune system’s 1st response to dangerous #Candida bloodstream infections.
This enables a non-invasive #test that delivers reliable results in minutes—a breakthrough vs. rising health threat.

Press release: tinyurl.com/3aychk8u
Paper: tinyurl.com/26pkne4u

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development | PNAS Invasive, high-mortality yeast infections caused by pathogenic Candida species are the most common fungal nosocomial bloodstream infections. The Wo...

Collaborative research uses glycan microarrays to decode Candida antibody responses in humans & mice. Results guide biomarker discovery and vaccine design—innovating fungal infection care.
🔗 www.pnas.org/doi/10.1073/...

#Innovation #FungalInfections #Vaccines #TeamScience

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development | PNAS Invasive, high-mortality yeast infections caused by pathogenic Candida species are the most common fungal nosocomial bloodstream infections. The Wo...

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development | PNAS www.pnas.org/doi/10.1073/...

🌍 TIMM 2025: Join the One Health Lunch Meeting on Sept 21, 2025 (12:30–2:00 PM, Room 3A)!
Topic: AMR – Fungal One Health Coalition for global strategies to combat AntiMycotic Resistance.
Hosts: Michaela Lackner & Paul Verweij.
🍴 Everyone welcome—bring your colleagues!

Great to be up and running at TIMM12 in Bilbao. @youngecmm.bsky.social @ecmmcandidaiv.bsky.social - a feast of medical mycology being basic and clinical mycology. @mrccmm.bsky.social @ishamycology.bsky.social @youngisham.bsky.social

Looking forward to our YECMM Dinner at @TiMM25 ☺️

📝Registration is still possible:
congresscare.eventsair.com/12th-trends-...

Fungal Pathogens: Emerging Threats and Future Challenges | Keystone Symposia Join us at the Keystone Symposia on Fungal Pathogens: Emerging Threats and Future Challenges, January 2026, in Breckenridge, with field leaders!

Just a few days left for scholarship and short talk submissions!
Science, snow, and exciting advances in fungal and immunology research🔬 🍄❄️Claim your spot! #KSFUNGALPATH26 www.keystonesymposia.org/conferences/...

Herzlichen Dank an #DanilaSeidel & @rosannesprute.bsky.social für die großartige Organisation der #MYK 2025! Mit Engagement, Überblick & Herz habt ihr Programm, Location & Gesellschaftsrahmen perfekt gestaltet – viele Details, große Entscheidungen, voller Erfolg!

Image © MedizinFotoKöln D. Hensen

📅 Thursday at MYK 2025 – Kick off with the Opening Ceremony & Keynote on global fungal strategies. Sessions on host-pathogen interaction, innovative therapies & pediatric infections. Explore posters, industry exhibits & join the welcome reception!

What a great start to #MYK2025! Inspiring keynotes, exciting talks & posters, and amazing networking at tonight’s gathering. Wonderful to reconnect with colleagues in mycology - looking forward to the next two days! 🌍🍄✨

Pictures: Dorothea Hensen/MFK

📅 Friday at MYK 2025 – Start with the Keynote on global fungal strategies. Sessions on diagnostics, Candida auris, host-pathogen interaction & dermatophytes. Don’t miss Myco-Mania quiz, posters, industry exhibits & the social evening!
👉 dmykg-kongress.de

🚨 The ECMM Candida IV Study is enrolling! Retrospective, multicentre, global study on non-albicans candidemia, antifungal resistance & outcomes.

🗓️ Retrospective enrolment: Apr 2024 – Sept 2025 | Data entry open until Mar 2026
🔗 Register your site now: app.carelane.io/1a85ade7-31c... | PIN: 8539

Communicable E34: WHO's Fungal Priority Pathogens List Fungal infections and disease have long been overlooked in terms of...

🎙️ Just published a new #Communicable episode: Communi...

Hosted by Angela Huttner @angelahuttner.bsky.social
Josh Nosanchuk @josh-nosanchuk.bsky.social

with invited guests:
Hatim Sati (@who.int)
Dimitrios Kontoyiannis (@mdanderson.bsky.social)

Listen here:

#IDSky #Clinmicro #MedSky

🌍 Save the Date: DZIF/PEG Joint Meeting 2026 – Bridging Disciplines in Infectious Diseases in the Era of Gender & Precision Medicine.
Austausch, Innovation & Kollaboration von Bench to Bedside.

Mehr Infos 👉 dzif-peg-annual-meeting.de
@dzif.bsky.social

Die #MYK2025 – 59. Jahrestagung der Deutschsprachigen Mykologischen Gesellschaft – findet vom 4.-6. September in Köln statt. Top-Expert:innen, neueste Forschung & spannende Themen rund um medizinische Mykologie! Mehr Infos & Anmeldung: dmykg-kongress.de #Mykologie

Candida and Candidiasis 2025 06 - 09 October 2025

Society Event Grant – applications for funding to attend Candida and Candidiasis 2025 are now open. Check your eligibility and apply before the deadline 23 June 2025 at 23:59 BST - microb.io/CandidaCandi...

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study Only a small number of antifungal therapies for invasive fungal disease (IFD) are currently available, and many pathogens are resistant to one or more…

New hope for hard-to-treat fungal infections: Phase 2b results show #Olorofim is effective and well-tolerated in patients with few or no treatment options.
Read in The Lancet Infectious Diseases 👉 www.sciencedirect.com/science/arti...
#IFD #Antifungals #ClinicalTrials

I'm very excited about this one, novel antifungal!

How a discovery in Yellowstone National Park led to the development of PCR - Richmond Scientific A discovery in Yellowstone National Park led to the development of PCR, the gold-standard COVID-19 tests used to fight the global pandemic.

Reminder: Nobel-prize winning PCR (1983), used in basically all genetic tech today, was only possible because of extremophile bacterium discovered in 1964 in Yellowstone funded by a small ~$80k NSF grant with no obvious application at the time. #science 🧪
www.richmondscientific.com/how-a-discov...

Please repost: We have a postdoc position in Antifungal Immunity Research available to study T cell responses and fungal sensitization in atopic dermatitis. @lableibundgut.bsky.social @neil-gow.bsky.social @mrccmm.bsky.social
For more details, visit: jobs.exeter.ac.uk/hrpr_webrecr...

Please repost: We are looking for a postdoc interested in Fungal Cell Wall Research to study the Malassezia-host interaction interface in the context of atopic dermatitis. @lableibundgut.bsky.social @neil-gow.bsky.social @mrccmm.bsky.social
For more details, visit: jobs.exeter.ac.uk/hrpr_webrecr...

Proud to present the progress of ECMM Candida IV study at #ISHAM2025

Still open for participation!

@martinhoenigl.bsky.social